Data highlight both SER-603's rational design that targets microbial functions linked to mucosal healing and gastrointestinal inflammation in IBD, as well as the advancement of microbiome-based biomarkers that inform response to biologics and patient stratification

Presentation selected for DDW ‘Poster of Distinction' recognition

CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB) (Seres or the Company), a leading live biotherapeutics company, today announced new preclinical data supporting the design and potential of SER-603, a next-generation cultivated live biotherapeutic candidate for inflammatory bowel disease (IBD), being presented at Digestive Disease Week (DDW) 2026, taking place May 2–5, 2026, in Chicago, IL. The poster, titled "The Rational Design of SER-603: A Next Generation Cultivated Microbial Consortia to Treat IBD," which has been selected as a DDW ‘Poster of Distinction,' highlights Seres' integrated approach to the design of microbiome therapeutics, combining rational strain selection and a novel biomarker-driven patient stratification.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.